Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3324)	7/2/2021 11:03:37 PM
From: A.J. Mullen	Respond to of 3557

Stat interview with George Yancoupolous. He mentions the collaboration with Intellia and Alnylam, statnews.com By the end of the year, we’ll have over 2 million humans sequenced, all linked to their electronic health records, so we can look for very rare mutations that are associated with either benefit or harms. So in the same vein, we’ve discovered dozens of protective mutations. The one that you’re referring to, that we’re just announcing now, is a protective gene against obesity.